Warner Chilcott to build 200-job facility; NICE gives final approval to Cimzia;

  @FiercePharma: FTC loses pay-for-delay claim against Solvay Article | Follow @FiercePharma

> Warner Chilcott announced it would establish a new Irish facility that would create up to 200 new jobs in County Louth. Release

> The U.K.'s National Institute for Health and Clinical Excellence gave a final green light for UCB Pharma's rheumatoid arthritis treatment Cimzia. Report

> Bayer will keep its dividend for 2009 unchanged--the first time since 2003 that the German drugs and chemicals company isn't increasing the annual payout. Report

> Mylan turned in a fourth-quarter profit--beating analysts' estimates--as the drugmaker saw its revenue increase by double digits on overseas strength. Report

> Indian drugmaker Ranbaxy Laboratories swung to a quarterly profit, helped by launching its copy of a blockbuster drug in the U.S., and forecast strong growth this year from new products. Report

> The U.S. Centers for Disease Control and Prevention recommended that all Americans over the age of 6 months should receive a flu shot every year, starting this fall. Report

> Sandoz has opened a new modified protein manufacturing facility in Slovenia to produce biosimilar epoetin alfa. Report

> India's pharmaceutical industry has grown to the third largest in the world by volume and ranks 14th in terms of value, a domestic survey of the industry concluded. Report

Biotech News

 @FierceBiotech: Is Obama backing down on biosimilars? Article | Follow @FierceBiotech

 @JohnCFierce: OrbiMed Advisors has raised $550 million for its new health venture fund, its largest ever. Most money for biotech. @JohnCFierce 

> In a big endorsement of Regulus Therapeutics, GlaxoSmithKline says it will follow up their two-year-old, $600 million pact aimed at finding new drugs for inflammatory diseases with a new, $150 million collaboration targeting microRNA-122 for hepatitis C. Report

> Even as Merck and Pfizer and other Big Pharma companies concentrate on big acquisitions and more external collaborations as a way of getting better at drug development, Eli Lilly CEO John Lechleiter has focused on pushing the company's R&D arm to work faster and smarter. Item

> Anthera Pharmaceuticals, a classic drug developer with high hopes and no steady income, opted to delay its initial public offering yesterday rather than brave the chilly investment scene. Story

> The FDA and the NIH say they'll collaborate on a new program aimed at improving the regulatory science used to review the safety and efficacy of new drugs, promising that better science will lead to swifter decision-making. Article

Manufacturing News

> Tobacco may speed vax production. Item

> Eli Lilly is the recent recipient of an FDA warning letter concerning adulterated API at a manufacturing facility in Puerto Rico. Story

> Some $750,000 later, the Ottawa International Centre for Infectious Diseases will not be building the HIV vaccine manufacturing plant it had designed to answer a government call. Article

Vaccines News

> Prevnar 13: Pfizer's next Lipitor? Item

> DARPA providing $40 million for tobacco vax project. Article

> A simple, single gene swap was all it took to create a hybrid bird and swine flu virus, according to an international team of scientists. Report

And Finally... Women older than 40 are unlikely to get much benefit from the vaccine for the virus that causes cervical cancer, a new study reports. Report